Plain-English translation of NCT03396718 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether patients with HPV-positive squamous cell carcinoma of the throat can be treated with lower doses of radiation after surgery, rather than the standard higher doses. The goal is to reduce long-term side effects like difficulty swallowing, dry mouth, and radiation-related complications, while keeping cancer control just as effective. The trial will carefully monitor patients to make sure the lower doses are safe before expanding to more people.
HPV-positive throat cancers tend to respond very well to treatment and have better survival rates than HPV-negative cancers. Researchers want to see if patients with HPV-positive tumors can receive gentler treatment — lower radiation doses — that would reduce painful and disabling long-term side effects while still keeping the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be assigned to a treatment group based on your HPV status and cancer stage. If you are HPV-positive, you may receive lower-dose radiation therapy as part of the de-escalation study. If you are HPV-negative, you will receive standard radiation or radiation with chemotherapy. All participants will have regular follow-up visits to check for side effects and cancer recurrence. The first group of 10 patients in each treatment level will be monitored closely for 2 years before the trial decides whether to continue with lower doses in additional patients.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Germany